Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Other solid neoplasm 2CNS 2Breast 2Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Breast Neoplasms 2Breast Neoplasms, Male 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 183Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 93Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × 1-methyltryptophan × Breast × Clear all
NCT01792050 2020-05-28

Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer

Lumos Pharma

Phase 2 Completed
169 enrolled
Breast

Breast Neoplasms

NCT01042535 2018-04-11

Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
44 enrolled 10 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡